Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
D 2.47 0.82% 0.02
EBS closed up 0.82 percent on Monday, March 18, 2024, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
New Uptrend Bullish 0.82%
Stochastic Buy Signal Bullish 0.82%
Wide Bands Range Expansion 0.82%
Oversold Stochastic Weakness 0.82%
New Downtrend Bearish 5.11%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 14 hours ago
Down 3% about 17 hours ago
Down 2 % about 18 hours ago
Down 1% about 18 hours ago
Up 2% about 18 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Emergent Biosolutions, Inc. Description

Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Solid Tumors Drugs Monoclonal Antibody FDA Influenza Vaccines Rheumatoid Arthritis Inflammatory Bowel Disease Vaccination Lotion Blood Plasma Chronic Lymphocytic Leukemia Lymphocytic Leukemia Decontamination Specialized Products Biodefense Host Disease Biological Warfare Graft Versus Host Disease Monkeypox Anthrax Chemical Warfare Naloxone Poxviruses Anthrax Vaccines Chemical Warfare Agents

Is EBS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.67
52 Week Low 1.42
Average Volume 3,533,147
200-Day Moving Average 3.96
50-Day Moving Average 2.21
20-Day Moving Average 2.78
10-Day Moving Average 2.68
Average True Range 0.34
RSI (14) 48.98
ADX 28.85
+DI 25.50
-DI 23.34
Chandelier Exit (Long, 3 ATRs) 2.71
Chandelier Exit (Short, 3 ATRs) 2.50
Upper Bollinger Bands 3.71
Lower Bollinger Band 1.86
Percent B (%b) 0.33
BandWidth 66.57
MACD Line 0.07
MACD Signal Line 0.17
MACD Histogram -0.1023
Fundamentals Value
Market Cap 128.15 Million
Num Shares 51.9 Million
EPS -15.56
Price-to-Earnings (P/E) Ratio -0.16
Price-to-Sales 0.08
Price-to-Book 0.12
PEG Ratio 1.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.70
Resistance 3 (R3) 2.69 2.60 2.66
Resistance 2 (R2) 2.60 2.55 2.61 2.64
Resistance 1 (R1) 2.54 2.51 2.50 2.55 2.63
Pivot Point 2.45 2.45 2.43 2.46 2.45
Support 1 (S1) 2.39 2.40 2.35 2.40 2.31
Support 2 (S2) 2.30 2.36 2.31 2.30
Support 3 (S3) 2.24 2.30 2.28
Support 4 (S4) 2.25